Home Cart Sign in  
Chemical Structure| 900510-03-4 Chemical Structure| 900510-03-4

Structure of Cligosiban
CAS No.: 900510-03-4

Chemical Structure| 900510-03-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PF-3274167 is a high-affinity nonpeptide oxytocin receptor (OTR) antagonist, with Ki of 9.5 nM.

Synonyms: PF-3274167

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cligosiban

CAS No. :900510-03-4
Formula : C19H19ClFN5O3
M.W : 419.84
SMILES Code : FC1=CC(Cl)=C(OC2CN(C3=NN=C(COC)N3C4=CC=C(OC)N=C4)C2)C=C1
Synonyms :
PF-3274167
MDL No. :MFCD25976681
InChI Key :HNIFCPBQMKPRCX-UHFFFAOYSA-N
Pubchem ID :11683187

Safety of Cligosiban

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Cligosiban

GPCR

Isoform Comparison

Biological Activity

Description
Cligosiban (PF-3274167), a non-peptide oxytocin receptor antagonist with high oral bioavailability and good brain penetration, exhibits high affinity (Ki=9.5 nM) and excellent selectivity against vasopressin receptors, particularly V1b and V1a subtypes. Cligosiban inhibits ejaculatory physiology in rodents[1][2].

In Vitro:

Cell Line
Concentration Treated Time Description References
Rat bladder tissue 1 µM and 10 µM Cligosiban significantly reduced the frequency of spontaneous contractions in both young and older rat bladders Biomedicines. 2024 Mar 18;12(3):674
NCI-H2373 45 μM 5 days To evaluate the antiproliferative effect of Cligosiban on MM cell lines with high OXTR expression. Results showed that Cligosiban significantly inhibited the proliferation of NCI-H2373 cells. Cancer Sci. 2021 Sep;112(9):3520-3532
Y-MESO-27 25 μM 5 days To evaluate the antiproliferative effect of Cligosiban on MM cell lines with high OXTR expression. Results showed that Cligosiban significantly inhibited the proliferation of Y-MESO-27 cells. Cancer Sci. 2021 Sep;112(9):3520-3532
NCI-H2052 15 μM 5 days To evaluate the antiproliferative effect of Cligosiban on MM cell lines with high OXTR expression. Results showed that Cligosiban significantly inhibited the proliferation of NCI-H2052 cells. Cancer Sci. 2021 Sep;112(9):3520-3532

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice NCI-H2052 xenograft model Oral 60 mg/kg Every other day for a total of 10 doses To evaluate the antitumor effect of oral Cligosiban on the NCI-H2052 xenograft model. Results showed that Cligosiban significantly inhibited tumor growth. Cancer Sci. 2021 Sep;112(9):3520-3532

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.38mL

0.48mL

0.24mL

11.91mL

2.38mL

1.19mL

23.82mL

4.76mL

2.38mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories